title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
AbbVie  ( ABBV )  Announces Appointment of New CEO Robert Michael,20240221T154300,https://www.zacks.com/stock/news/2229455/abbvie-abbv-announces-appointment-of-new-ceo-robert-michael,ABBV,0.714592,Somewhat-Bullish,0.343678
Report Forecasts Promising Future for Alzheimer's Disease Market with New Therapeutic Approaches | Brandessence Market Research,20230515T093200,https://www.prnewswire.com/news-releases/report-forecasts-promising-future-for-alzheimers-disease-market-with-new-therapeutic-approaches--brandessence-market-research-301824407.html,ABBV,0.017394,Neutral,-0.017349
"Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study",20220802T122759,https://www.benzinga.com/general/biotech/22/08/28308082/biotech-daily-trial-setback-for-eliem-therapeutics-allarity-drops-work-on-cancer-monotherapies-ax,ABBV,0.157483,Neutral,0.079368
"Open-Angle Glaucoma Market Size and Share to Accelerate Substantially by 2032, Predicts DelveInsight | Key Companies in the Market - SPARC, AbbVie, Ocuphire, Santen, Glaukos, Ocular Therapeutix, VivaVision Biotech, MediPrint Ophthalmics",20231012T210100,https://www.prnewswire.com/news-releases/open-angle-glaucoma-market-size-and-share-to-accelerate-substantially-by-2032-predicts-delveinsight--key-companies-in-the-market---sparc-abbvie-ocuphire-santen-glaukos-ocular-therapeutix-vivavision-biotech-mediprint-ophth-301954523.html,ABBV,0.051276,Neutral,0.079668
"The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight",20231122T220100,https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-b-cell-lymphomas-diffuse-large-b-cell-lymphoma-follicular-lymphoma-chronic-lymphocytic-leukemia-mantle-cell-lymphoma-marginal-zone-lymphoma-waldenstrom-macroglobulinemia-and-burkitt-lymphoma--301995626.html,ABBV,0.039505,Neutral,0.102193
"The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More",20220414T133544,https://www.benzinga.com/general/biotech/22/04/26630399/the-daily-biotech-pulse-pfizer-biontech-covid-19-booster-data-in-kids-regenerons-covid-19-therapy,ABBV,0.08395,Neutral,0.011626
Tuniu  ( NASDAQ:TOUR )  Stock Rating Lowered by StockNews.com,20230218T081645,https://www.defenseworld.net/2023/02/18/tuniu-nasdaqtour-stock-rating-lowered-by-stocknews-com.html,ABBV,0.092927,Neutral,0.107507
Tuniu  ( NASDAQ:TOUR )  Stock Rating Lowered by StockNews.com,20220826T070646,https://reporter.am/2022/08/26/tuniu-nasdaqtour-stock-rating-lowered-by-stocknews-com.html,ABBV,0.149656,Neutral,0.135655
48 Stocks Moving In Friday's Mid-Day Session,20220429T162716,https://www.benzinga.com/news/22/04/26904587/48-stocks-moving-in-fridays-mid-day-session,ABBV,0.066011,Neutral,0.000443
70 Biggest Movers From Friday,20220502T094646,https://www.benzinga.com/news/22/05/26923653/70-biggest-movers-from-friday,ABBV,0.05261,Somewhat-Bearish,-0.321513
"Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In - Corbus Pharmaceuticals  ( NASDAQ:CRBP ) , AbbVie  ( NYSE:ABBV ) ",20240514T173240,https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38803783/will-pharma-and-healthcare-have-competitive-edge-in-cannabis-post-rescheduling-data,ABBV,0.088964,Neutral,-0.089544
Roche's  ( RHHBY )  Lunsumio Application Gets Priority Review,20220706T171700,https://www.zacks.com/stock/news/1948787/roches-rhhby-lunsumio-application-gets-priority-review,ABBV,0.048681,Neutral,0.000723
"Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Bayer, Merck, Insmed, Acceleron, AbbVie, Alnylam, Apnimed, AstraZeneca, Gossamer Bio",20230719T210100,https://www.prnewswire.com/news-releases/hypertension-market-to-accelerate-positively-estimates-delveinsight--key-companies-active-in-the-market---novartis-bayer-merck-insmed-acceleron-abbvie-alnylam--apnimed-astrazeneca-gossamer-bio-301880558.html,ABBV,0.049577,Neutral,0.059691
"Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo",20231004T210100,https://www.prnewswire.com/news-releases/small-cell-lung-cancer-market-to-accelerate-substantially-during-the-study-period-20192032-assesses-delveinsight--leading-companies----amgen-novartis-abbvie-bms-clovis-oncology-cardiff-oncology-roche-daiichi-sankyo-301946615.html,ABBV,0.086948,Neutral,-0.051258
"Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight | Key Companies - Merck, Theradex, SynerGene, Mirati, Novartis, Syntrix Biosystems, Eli Lilly, Boehringer Ingelheim",20230803T210100,https://www.prnewswire.com/news-releases/pancreatic-endocrine-tumor-market-is-expected-to-expand-at-a-healthy-growth-rate-by-2032-assesses-delveinsight--key-companies---merck-theradex-synergene-mirati-novartis-syntrix-biosystems-eli-lilly-boehringer-ingelheim-301892397.html,ABBV,0.02074,Neutral,-0.020974
MacroGenics  ( MGNX )  Q4 2023 Earnings Call Transcript,20240308T053017,https://www.fool.com/earnings/call-transcripts/2024/03/08/macrogenics-mgnx-q4-2023-earnings-call-transcript/,ABBV,0.012228,Neutral,0.073709
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20230703T210100,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,ABBV,0.020404,Neutral,-0.005463
Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain,20230626T210100,https://www.prnewswire.com/news-releases/antibody-drug-conjugates-clinical-trial-pipeline-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-180-companies-working-in-the-domain-301862784.html,ABBV,0.020903,Neutral,0.064977
"I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022",20220830T100000,https://www.prnewswire.com/news-releases/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-six-months-ended-june-30-2022-301614531.html,ABBV,0.05035,Neutral,0.12269
"I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021",20220329T101000,https://www.prnewswire.com/news-releases/i-mab-provides-business-and-corporate-updates-and-reports-financial-results-for-the-year-ended-december-31-2021-301512585.html,ABBV,0.027123,Neutral,0.05172
Molecular Partners AG  ( MOLN )  Q4 2021 Earnings Call Transcript,20220316T190029,https://www.fool.com/earnings/call-transcripts/2022/03/16/molecular-partners-ag-moln-q4-2021-earnings-call-t/,ABBV,0.011216,Bullish,0.523568
CoolSculpting® Elite Announces First Ever CoolMonth - Investing News Network,20230403T124033,https://investingnews.com/coolsculpting-r-elite-announces-first-ever-coolmonth/,ABBV,0.100518,Neutral,0.079514
Tissue Engineering Market is Expected to Reach $8.9 Billion | MarketsandMarkets™,20240122T123000,https://www.benzinga.com/pressreleases/24/01/g36713761/tissue-engineering-market-is-expected-to-reach-8-9-billion-marketsandmarkets,ABBV,0.03792,Neutral,-0.040123
